RET/PTC Inhibitors
2 drugsAbout RET/PTC
The rearranged during transfection/papillary thyroid carcinoma (RET/PTC) fusion protein results from chromosomal rearrangements, creating constitutively active kinases that drive cell proliferation and survival. The fusion involves the tyrosine kinase domain of the RET receptor and various N-terminal partners. It functions as an oncogenic driver.
RET/PTC is a therapeutic target in oncology, though no direct genetic evidence currently links it to specific diseases. Its role as an oncogenic driver makes it a valuable target for cancer therapies. Inhibiting RET/PTC activity can disrupt cancer cell growth.
Two approved drugs, including SORAFENIB TOSYLATE (NEXAVAR), target RET/PTC, both are small molecules. These drugs, developed by Viatris and Bayer, are approved for oncology and other therapeutic areas. Further development of selective inhibitors is possible.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Fibrolamellar Carcinoma with only 2 trials.
- phase2 represents biological uncertainty with 57% completion.
Top RET/PTC Drugs
The competitive landscape includes Viatris and Bayer, the companies with approved drugs.
Limited competition suggests opportunity for new entrants with differentiated RET/PTC inhibitors.
RET/PTC Drug Modality Landscape
Modalities
Routes of Administration
RET/PTC is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation and novel IP.
RET/PTC Clinical Trials 379 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 155 | 113 | 33 | 8 | 77% |
| Phase 2 | 166 | 98 | 46 | 21 | 68% |
| Phase 3 | 53 | 34 | 11 | 8 | 76% |
| Phase 4 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
RET/PTC Drug Approval Timeline (2005 - 2020)
The first drug was approved in 2005 (NEXAVAR), and the most recent in 2020 (SORAFENIB TOSYLATE).
The 16-year span between approvals indicates a potentially underserved market with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 113 clinical trials targeting RET/PTC.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities